Bogart Wealth LLC Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

Bogart Wealth LLC reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 81.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,844 shares of the company's stock after selling 25,993 shares during the quarter. Bogart Wealth LLC's holdings in Johnson & Johnson were worth $969,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $29,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent research reports. Morgan Stanley reissued an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Barclays lowered their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Bank of America lowered their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $171.00.

Johnson & Johnson Stock Up 0.0%

Shares of NYSE:JNJ opened at $156.91 on Tuesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The firm has a market capitalization of $377.55 billion, a P/E ratio of 17.45, a P/E/G ratio of 2.14 and a beta of 0.41. The stock has a 50 day moving average price of $153.79 and a 200-day moving average price of $154.63. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.